Bacticort

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bacticort

Quick Facts

Property Description
Active Ingredients Betamethasone Dipropionate, Gentamicin Sulfate
Form Topical Cream or Ointment
Pharmacological Class Corticosteroid-Antibiotic Combination
Origin Synthetic (Glucocorticosteroid and Aminoglycoside)

What Type of Medicine is Bacticort?

Bacticort is a prescription topical dermatological agent that functions as a fixed-dose combination product, intended exclusively for application to the skin. It is structurally classified as a corticosteroid-antibiotic combination, reflecting its specialized composition designed to provide two complementary therapeutic actions in a single preparation. This medicinal entity is strictly for cutaneous use, and it is available in two common forms: an ointment and a cream.


What is Bacticort Made Of?

The functional profile of Bacticort is defined by its two active ingredients: the potent synthetic glucocorticosteroid, Betamethasone Dipropionate, and the broad-spectrum aminoglycoside antibiotic, Gentamicin Sulfate. The formulation combines the powerful anti-inflammatory action of the corticosteroid with the anti-infective properties of the antibiotic within an emollient base. Betamethasone Dipropionate is clinically recognized for its high potency among topical corticosteroids, distinguishing it from milder options. The specific pairing with Gentamicin Sulfate differentiates Bacticort from simple anti-inflammatory creams, creating a specialized product for managing complex skin issues.


What is the General Purpose of This Combination?

The general purpose of this dual-action product is to offer comprehensive management for inflammatory skin conditions that are concurrently complicated by, or at high risk of developing, a secondary bacterial infection. The corticosteroid component provides a rapid anti-inflammatory effect and anti-pruritic effect, alleviating severe symptoms like redness and itching. The antibiotic component, Gentamicin Sulfate, provides a direct bactericidal effect against susceptible organisms. The combination of a high-potency corticosteroid and an antibiotic addresses both the inflammatory and microbial elements simultaneously. This targeted strategy focuses on stabilizing the affected area and promoting skin recovery.

Regulatory References

  1. Betamethasone Dipropionate - DailyMed - NIH

What side effects are possible with Bacticort?

Possible Side Effects and Safety Information

The safety profile for Bacticort is structured around two main categories of risks derived from its components and class of action: nephrotoxicity and atypical fractures.

Serious and Clinically Significant Adverse Reactions

Adverse Reaction Category Key Findings from Regulatory Sources
Nephrotoxicity (Kidney Damage) Changes in kidney function, including potential damage or failure, are often associated with the use of the injectable form. This risk led to the U.S. FDA requesting the market withdrawal of Bacitracin for injection due to the severity and availability of safer alternatives. Kidney function must be closely monitored during therapy.
Anaphylactic Reactions Sudden, severe, and potentially life-threatening allergic reactions have been reported, even following initial doses. Health Canada requested a Serious Warnings and Precautions Box to strengthen information on this risk and on kidney toxicity.
Atypical Femur Fractures This drug belongs to the bisphosphonate class, which has been associated with a very uncommon risk of atypical subtrochanteric and diaphyseal femur fractures. These fractures occur in the thigh bone with minimal or no trauma. The risk may be related to the long-term use of this class of medication.

Safety Monitoring and Limitations

Official safety documents indicate that kidney function changes may resolve if treatment is stopped early. For the bisphosphonate class, dull or aching pain in the thigh or groin may precede a complete atypical fracture by weeks to months. Due to the uncertainty regarding the optimal duration of use, discontinuation of the bisphosphonate component may be considered in patients with evidence of a femoral shaft fracture.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Bacticort is defined by the risks associated with the systemic absorption of its two active ingredients, which can occur with application over large areas, for prolonged periods, or under occlusive dressings.

Documented Overdose Manifestations

Component Manifestations and Risks
Corticosteroid The greatest risk is reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, which may lead to manifestations of Cushing's syndrome. Metabolic abnormalities like hyperglycemia and glucosuria are also documented. Management involves gradual drug withdrawal and possible use of supplemental systemic corticosteroids if withdrawal symptoms occur.
Gentamicin Systemic absorption, particularly when applied to large wounds or denuded skin, carries a risk of aminoglycoside toxicity. This may result in damage to the eighth cranial nerve, potentially causing irreversible ototoxicity (hearing loss) and nephrotoxicity (kidney damage).

When to Seek Urgent Medical Attention

Regulatory labeling mandates that if accidental ingestion occurs, individuals must seek medical help immediately or contact a Poison Control Center. Pediatric patients are noted to be more susceptible to systemic toxicity due to their body mass ratio, and toxicity risks are enhanced in the elderly and those with existing renal or hepatic impairment. Close clinical observation and monitoring tests are required if systemic overdose is suspected.

Therapeutic Uses of Bacticort

The Betamethasone Dipropionate/Gentamicin Sulfate combination is a specialized topical agent generally used when two distinct therapeutic needs—addressing symptoms related to inflammation and symptoms related to bacterial presence—are present within a skin condition. Its utility is centered on providing supportive relief across two main symptom domains. This combination is relevant for the management of infected lesions.

Dual-Action Relief for Secondarily Infected Skin Rashes

This medication is primarily used for steroid-responsive inflammatory skin conditions that are either complicated by or are at high risk of developing a superficial bacterial infection. This covers underlying dermatoses such as eczema, certain types of contact dermatitis, and psoriasis when visible signs of microbial contamination are present. By addressing the co-existing symptoms of inflammation and bacterial presence, it supports the skin during the acute phase of symptomatic management.

Controlling Severe Inflammation and Intractable Itching

Bacticort is commonly used to help with intensive symptomatic relief for acute, distressing manifestations, including pronounced pruritus (intense itching), visible erythema (redness), and edema (swelling). The application of this product assists in managing the intense symptoms and, as part of symptomatic relief, helps interrupt the itch-scratch cycle. This action contributes to easing the overall symptom load and supports improved day-to-day comfort during the heightened phase of the flare-up.


Quick Fact: Relief for Complicated Dermatoses

Symptom Domain Symptoms Managed Primary Benefit
Inflammation Severe Pruritus, Redness, Swelling Easing overall symptom load
Bacterial Presence Bacterial Contamination Assisting with functional stability

Regulatory References

  1. DailyMed overview from the National Library of Medicine

Eligibility and Restrictions for Use

Who Can and Cannot Use Bacticort?

Bacticort (often a combination of an antibiotic and a corticosteroid) is typically prescribed to manage inflammatory skin conditions where a bacterial infection is present or suspected. Use is generally restricted to patients with a confirmed indication, and the drug should only be applied externally as directed by a healthcare professional.


Who Can Use Bacticort?

Patient Group Indication
Adults and Children Certain inflammatory dermatoses (like eczema, psoriasis) complicated by a secondary bacterial infection or where bacterial infection is likely.
Patients with Otitis Externa Certain formulations are approved for external ear canal infections, as indicated by the specific product labeling.

Who Cannot Use Bacticort (Contraindications)?

Bacticort is contraindicated in several specific instances, primarily due to the risk of exacerbating other conditions or potential systemic absorption of the steroid component.

Contraindication Reason
Hypersensitivity Known allergy to any component of the formulation (e.g., the antibiotic, the corticosteroid, or excipients).
Viral Infections Skin lesions caused by viruses (e.g., herpes simplex, varicella), tuberculosis, or fungal infections, as the steroid can worsen these conditions.
Perioral Dermatitis/Acne Rosacea Topical steroid use in these areas can often lead to deterioration.
Perforated Eardrum Use in the ear canal is contraindicated if the tympanic membrane is perforated, due to the risk of ototoxicity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Bacticort, a topical corticosteroid-antibiotic, describes interaction patterns that are conditional upon significant systemic absorption of its active ingredients, Betamethasone Dipropionate and Gentamicin Sulfate.

Pharmacokinetic and Exposure Interactions Co-administration with strong CYP3A4 inhibitors, such as ritonavir or cobicistat-containing products, may inhibit the metabolic clearance of the Betamethasone component. This pharmacokinetic interaction can increase the systemic exposure to the corticosteroid, which, if sufficiently absorbed, raises the potential for systemic effects. Additionally, concurrent use of other topical or systemic corticosteroid-containing products may increase the total systemic exposure of Betamethasone.

Pharmacodynamic and Additive Toxicity Following significant systemic absorption, the Gentamicin component may interact pharmacodynamically with other medicines. Specifically, there is a documented risk of intensifying and prolonging the respiratory depressant effects of Neuromuscular Blocking Agents (NMBAs). Furthermore, to mitigate the risk of additive systemic toxicity, regulatory documents advise avoiding concurrent or sequential co-administration with other potentially nephrotoxic or neurotoxic agents, including other systemic aminoglycosides.

Population-Specific Risk Notes The susceptibility to these systemic interactions is heightened in specific patient populations. Due to an increased skin-surface-area-to-body-mass ratio, pediatric patients may absorb proportionally larger amounts, making them more susceptible to systemic toxicity. Patients with renal impairment also face a heightened risk of Gentamicin-related systemic effects due to reduced clearance.

Mechanism of Action

Bacticort, a combination drug, exerts its effect through two primary, distinct mechanistic domains: anti-inflammatory signaling and protein synthesis inhibition.

Glucocorticoid Receptor-Mediated Anti-Inflammation

This domain involves the corticosteroid component, which acts within receptor-mediated signaling pathways by binding to the cytoplasmic Glucocorticoid Receptor (GR). The activated GR complex then translocates to the cell nucleus, where it modifies early molecular steps by repressing the transcription of genes for pro-inflammatory mediators like cytokines and chemokines. This initiates or suppresses signaling sequences that ultimately contributes to the modulation of heightened physiological signaling by restricting the impact of elevated mediator concentrations.


Bacterial Protein Synthesis Suppression

This domain is mediated by the antibiotic component, which engages mechanisms that regulate overactive processes in susceptible bacteria. It targets the bacterial ribosome, suppressing essential signaling sequences by inhibiting the synthesis of proteins required for bacterial growth and multiplication. This molecular modification affects systems where specific transmitters or mediators dominate, such as bacterial replication machinery. The resulting physiological effect is an adjustment of pathway activity, reducing the replication rate of susceptible bacteria.

Dosage and Administration Information

Bacticort, a combination product containing Betamethasone Dipropionate and Gentamicin Sulfate, is approved solely for topical (cutaneous) use, available in both a cream and an ointment formulation. The general principle of administration is to apply a thin film of the preparation, sufficient to cover the affected skin area, typically once or twice daily.

The application course is designated as time-limited, reflecting the high potency of the corticosteroid component. If a sufficient clinical response is not achieved within a defined period, such as two to four weeks, the continuance of treatment requires professional reassessment. Furthermore, a constraint on total quantity applied is established, with application generally advised not to exceed 50 g per week.

Strict procedural conditions govern the medicine's use. Bacticort is not for application to the face, groin, or underarms, nor is it to be used beneath occlusive dressings or bandages, to mitigate the risk of increased systemic absorption. Regarding specific populations, the product is not recommended for use in children under the age of 12 or 13.

This focused administration protocol defines Bacticort as a highly localized, short-term treatment characterized by specific requirements for frequency of application and restrictions on the treated area.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bacticort


Evidence for Use in Inflammatory Skin Conditions Complicated by Infection

Clinical research examined the use of the combination agent (Betamethasone Dipropionate/Gentamicin Sulfate) in conditions characterized by fluctuating or episodic manifestations when bacterial presence was a factor. Short-term Randomized Controlled Trials (RCTs) were used to observe how symptoms were measured over intervals typically lasting only a few weeks. Research monitored clinical signs, such as redness and itching, and assessed changes in microbial presence in adult and adolescent populations. Research describes changes measured in these signs and symptoms during the acute treatment phase.

Studies Comparing the Combination to Monotherapy

The clinical evidence was evaluated in trials that compared the combined agent against the corticosteroid component alone. This research explored whether the inclusion of the antibiotic component resulted in a measured difference in study outcomes. Findings were mixed regarding the measured difference between the two treatments across various infected dermatoses. Comparative evidence is lacking in some specific disease contexts, and certainty remains low due to modest sample sizes, meaning that the results apply only to the populations studied.

Establishing the Potency of the Corticosteroid Component

Research also describes non-clinical pharmacodynamic studies conducted in healthy adult volunteers to confirm the high potency classification of the Betamethasone Dipropionate component. Findings suggest patterns consistent with the expected high potency of the steroid. This research monitored the skin blanching response, which is a surrogate biomarker of potency, not a measure of clinical efficacy in diseased skin.

Long-Term Studies and What Remains Uncertain

Clinical trials largely monitored the acute phase, and consequently, the follow-up durations were limited, generally ranging from 2 to 4 weeks. Evidence is limited regarding outcomes for long-term use, durability of observed patterns, or the potential development of microbial resistance. Data for certain groups remain insufficient for populations such as children and older adults.

Key Studies & References

  1. Label: BETAMETHASONE DIPROPIONATE cream - DailyMed (Basis for studied populations and follow-up duration)
  2. Label: GENTAMICIN SULFATE cream - DailyMed (Basis for antibiotic component use and susceptible bacteria)
  3. NICE Guidance: Summary of the evidence on secondary bacterial infection of eczema (Informs mixed findings on added benefit)
  4. Systematic review: Topical corticosteroids - Systematic review of treatments for atopic eczema (Informs general evidence limitations and comparators)

Frequently Asked Questions (FAQ)

Common questions about Bacticort (FAQ)

Q: What is the difference between Bacticort and [Similar Drug Name]?

According to the official product information, Bacticort is a combination medicine containing two distinct active components. It is composed of Betamethasone Dipropionate, which is a high-potency corticosteroid (anti-inflammatory), and Gentamicin Sulfate, which is an aminoglycoside antibiotic. Clarification on differences between Bacticort and another medicine can be aided by comparing the classes and potencies of the active ingredients.


Q: Are there different strengths of Bacticort?

Regulatory documents state that this medicine is available in both a cream formulation and an ointment formulation. Official prescribing documents contain the specific concentration strengths of the active ingredients within these two different formats.


Q: Is it common to feel nauseous when starting Bacticort?

Side effects like nausea and vomiting have been described in association with the use of systemic corticosteroids or aminoglycosides. These effects may occur if significant systemic absorption of the topical medicine happens. The official product information outlines the most important potential adverse reactions.


Q: Can Bacticort be used with other topical ointments?

Official instructions state that the medicine should not be used beneath occlusive dressings or bandages, as this significantly increases the absorption of the ingredients into the body. To avoid unintended systemic effects or potential interactions, it is important to discuss the use of any other topical products with a healthcare provider.


Q: How long after stopping Bacticort does it stay in your system?

If the active components are significantly absorbed into the body (systemic absorption), they are cleared over time. The Gentamicin antibiotic component, for instance, has an elimination half-life that is described as approximately 7 hours in individuals with normal kidney function.


Q: What is the half-life of Bacticort?

The half-life refers to the time it takes for half of the medicine to be eliminated from the body. The Gentamicin antibiotic component, if systemically absorbed, has an elimination half-life that is described as approximately 7 hours in individuals with normal kidney function.


Q: How does the medicine get into the body (absorption) after use?

Bacticort is designed for topical use on the skin. Following application, a small amount of the active ingredients may be absorbed through the skin (percutaneous absorption) and enter the body's overall circulation. Systemic absorption is generally minimized with proper application.


Q: Can Bacticort be taken long-term?

Regulatory documents advise that the application course must be time-limited. Treatment should generally not exceed two to four weeks due to the high potency of the corticosteroid component, which carries an increased risk of systemic effects with prolonged use.


Q: Is Bacticort available over the counter, or is it prescription only?

Bacticort is designated as a prescription-only medicine (Rx). Official information states that the product is restricted by Federal law to use by or on the order of a licensed practitioner.


Q: What should I do if I accidentally take more Bacticort than directed?

Systemic absorption of the topical medicine beyond recommended levels may lead to signs of hypercortisolism (Cushing's Syndrome) or, rarely, signs of Gentamicin toxicity. Patients are generally monitored for signs of adrenal gland suppression if excessive amounts are used.


Q: Is Bacticort appropriate for elderly patients?

While the product is not explicitly contraindicated, the risk of systemic effects from the Gentamicin component is heightened in patient populations that may have reduced kidney function. This factor is often associated with increasing age, meaning caution is often described in regulatory documents.


Q: Can Bacticort be used by people with kidney problems?

Patients with renal impairment face a heightened risk of systemic effects from the Gentamicin component due to reduced clearance (how the body eliminates the drug). Official documents indicate that close monitoring of kidney function is described as necessary during use in this population.


Q: What official studies or research are cited for Bacticort?

Official documents cite clinical trials that examined the combination agent's use in inflammatory skin conditions complicated by infection. Findings from these studies were included in the regulatory submission to support the approved uses of the medicine.


Q: Has Bacticort been studied in diverse patient populations?

Clinical evidence notes that research was conducted in adult and adolescent populations, and follow-up durations were limited. Research outlines that data for certain groups, such as children and older adults, remain insufficient based on the available studies.


Q: Is it normal to feel a mild burning sensation when using Bacticort cream?

The local side effects described in official documents for topical Betamethasone Dipropionate include burning, itching, and redness of the skin at the application site. These types of skin reactions may be mild or temporary.


Q: Is there a generic version of Bacticort available?

The active ingredients, Betamethasone Dipropionate and Gentamicin Sulfate, are generally available as lower-cost generic versions of the single-ingredient products. This is noted in official drug approval literature.


Q: Can Bacticort cause changes in appetite or weight?

Systemic absorption of the corticosteroid component may lead to systemic effects. These effects can include symptoms such as weight gain or changes in appetite, which are commonly associated with systemically administered steroid medicines.


Q: Is Bacticort known to be addictive?

The corticosteroid component belongs to a class of medicines for which cutaneous and psychological dependence has been described in published literature. This phenomenon, sometimes called Topical Corticosteroid Dependence, is described as leading to potential withdrawal or rebound symptoms upon stopping the medicine.


Q: Is Bacticort safe to use if I have diabetes?

Topical corticosteroids can sometimes increase blood sugar levels through systemic absorption. Official warnings note that individuals with diabetes are described as needing close monitoring of blood glucose levels due to the risk of increased blood sugar from systemic absorption.


Q: Are there any specific laboratory tests recommended while taking Bacticort?

Official documents advise that the patient's kidney function should be closely monitored during therapy. This recommendation is made especially if there is concern for significant systemic absorption of the Gentamicin antibiotic component.


Q: How does the body get rid of Bacticort?

Once absorbed, the Gentamicin component is eliminated from the body primarily through the kidneys (renal excretion) by a process called glomerular filtration. Information on how the body clears the active ingredients is included in the pharmacokinetics section of the official label.


Q: Can I store Bacticort in the refrigerator?

Storage instructions state the product should be kept out of the reach of children and protected from direct sunlight. It must be stored below 30 C (or 86 F) and must not be frozen. Any storage within this temperature range maintains product stability.


Q: Can Bacticort cause skin irritation or redness?

Local side effects described in the official product information for topical Betamethasone Dipropionate include burning, itching, and redness of the skin at the application site. These are common reactions associated with the use of the topical corticosteroid component.


Q: What are the official restrictions on where Bacticort should be applied on the body?

Official documents explicitly state the medicine should not be applied to the face, groin, or underarms. Furthermore, it should not be used beneath occlusive dressings or bandages to minimize the risk of increased systemic absorption.

How should Bacticort be stored and disposed of?

How to Store and Dispose of Bacticort?

Official regulatory documents define strict requirements for the storage and disposal of this topical medicine to ensure stability and safety.

Storage Conditions

Constraint Requirement
Temperature Do not store above 30 C.
Freezing Do not freeze the product.
Light Protection Must be protected from direct sunlight.
Container Integrity Do not use if the container seal is broken.

Storage must adhere to a temperature maximum of 30 C and explicitly prohibits freezing to maintain product stability. Protection from sunlight is required. For child safety, the medicine must be stored out of the sight and reach of children. Any disposal of unused or expired product must be done strictly according to local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bacticort found in:

A-Z Index: